Your session is about to expire
← Back to Search
Checkpoint Inhibitor
Nivolumab 360mg for Kidney Cancer
Phase 2
Waitlist Available
Research Sponsored by Michael B. Atkins, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Summary
This trial is testing a new cancer drug in 120 patients who have not had any other treatment for their kidney cancer.
Eligible Conditions
- Kidney Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Secondary outcome measures
Clinical Activity (Complete Response (CR), Partial Response (PR) and Stable Disease (SD)
Objective Response Rate (CR/PR)
Progression Free Survival (PFS) at one year
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: PART B: Nivolumab + IpilimumabExperimental Treatment3 Interventions
Nivolumab 3mg/kg and Ipilimumab 1mg/kg; Nivolumab 360mg
Group II: PART A: NivolumabExperimental Treatment2 Interventions
Nivolumab 240mg; Nivolumab 360mg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab 360mg
2019
Completed Phase 2
~10
Find a Location
Who is running the clinical trial?
Michael B. Atkins, MDLead Sponsor
1 Previous Clinical Trials
120 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,652 Previous Clinical Trials
4,130,585 Total Patients Enrolled
Hoosier Cancer Research NetworkOTHER
68 Previous Clinical Trials
3,592 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger